|1.||Mills, Gordon B: 2 articles (04/2006 - 04/2006)|
|2.||Wang, Xue: 1 article (05/2015)|
|3.||Zou, Yejun: 1 article (05/2015)|
|4.||Loscalzo, Joseph: 1 article (05/2015)|
|5.||Yang, Kai: 1 article (05/2015)|
|6.||Yang, Yi: 1 article (05/2015)|
|7.||Yi, Jing: 1 article (05/2015)|
|8.||Tang, Yun: 1 article (05/2015)|
|9.||Chen, Lixin: 1 article (05/2015)|
|10.||Chen, Xianjun: 1 article (05/2015)|
05/05/2015 - "Among > 5,500 unique compounds, we identified KP372-1 as a potent NQO1-mediated redox cycling agent that produced extreme oxidative stress, selectively induced cancer cell apoptosis, and effectively decreased tumor growth in vivo. "
04/01/2006 - "To explore the effect of Akt inhibition on the growth and survival of HNSCC tumors, we evaluated the effect of a novel Akt inhibitor, KP372-1, on the growth, survival, and sensitivity to anoikis of HNSCC cell lines in culture. "
01/01/2012 - "In addition, the newly developed inhibitors ZSTK474 and KP372-1 which selectively target pan-class I PI3K and Akt, respectively, and Rapamycin which has been well-established as highly specific mTOR inhibitor, decrease viability of canine cancer cell lines. "
|2.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|3.||Thyroid Neoplasms (Thyroid Cancer)
05/23/2005 - "As thyroid cancer consistently expresses phosphorylated Akt and KP372-1 effectively blocks Akt signalling, further preclinical evaluation of this compound for treatment of thyroid cancer is warranted."
05/23/2005 - "We demonstrated that Akt is highly phosphorylated in thyroid cancer cell lines and human thyroid cancer specimens, and hypothesised that KP372-1, an Akt inhibitor, would block signalling through the PI3K pathway and inhibit cell proliferation while inducing apoptosis of thyroid cancer cells. "
05/23/2005 - "The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells."
|4.||Head and Neck Neoplasms (Head and Neck Cancer)
|1.||fms-Like Tyrosine Kinase 3